Many patients with chronic conditions may have low antibodies after second COVID-19 vaccine

In a new study, Michael E. Wechsler, director of the National Jewish Health Cohen Family Asthma Institute [and professor of medicine at CU School of Medicine], and colleagues identified 360 patients (mean age, 62 years; 63% women) with chronic medical conditions evaluated at the respiratory specialty clinic who received two doses of the Pfizer/BioNTech (64%) or Moderna (36%) mRNA vaccines from December 2020 to July 2021 and subsequently had spike antibody results at least 14 days following the second dose.